文献速递瓣膜外科

经颈动脉途径经导管主动脉瓣置换术五年结局

Five-year outcomes of transcarotid transcatheter aortic valve replacement.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-06-25

本研究前瞻性纳入110例连续接受经颈动脉途径经导管主动脉瓣置换术(TC-TAVR)的患者,评估5年复合终点(全因死亡、卒中、再住院)发生率为54.5%。5年随访时瓣膜血流动力学、NYHA心功能分级和生活质量改善持续存在,生物瓣衰败发生率为0.9%。作者认为结果提示TC-TAVR的长期安全性和有效性,支持其作为非股动脉入路候选者的替代手术方法。

要点

  • TC-TAVR术后5年复合终点(全因死亡、卒中、再住院)发生率为54.5%。
  • 全因死亡45.6%(11.9/100患者年),卒中8.2%(1.9/100患者年),致残性卒中2.7%(0.7/100患者年),再住院27.2%。
  • 瓣膜血流动力学、NYHA分级和EQ-VAS的改善持续至5年(P < .001),生物瓣衰败发生率0.9%。

核心结论

  • 约半数中高危患者接受TC-TAVR后5年随访无主要心血管事件存活。
  • 卒中年发生率低,瓣膜血流动力学、功能状态和生活质量的早期改善持续至5年。
  • 结果提示TC-TAVR的长期安全性和有效性,支持该入路作为非股动脉候选者替代手术的方法。

研究设计与样本

  • 前瞻性纳入110例连续接受TC-TAVR的患者,基线、手术和随访数据收集于专用数据库。
  • 主要终点为5年随访时全因死亡、卒中和再住院复合结局的发生率。
  • 随访期间检查超声心动图结果、NYHA心功能分级和EQ-VAS评估的生活质量。

主要发现

  • 患者中位年龄77岁(IQR 72-82.2岁),女性占42.3%,STS风险评分中位数5.02%(IQR 3.4%-7.5%)。
  • 复合主要终点发生率为54.5%;全因死亡45.6%(11.9/100患者年),卒中8.2%(1.9/100患者年),致残性卒中2.7%(0.7/100患者年),再住院27.2%。
  • 术后瓣膜血流动力学、NYHA分级和EQ-VAS的改善持续至5年随访(P < .001)。
  • 生物瓣衰败发生率为0.9%。

临床怎么用

  • 原文结论认为结果提示TC-TAVR的长期安全性和有效性,支持该入路作为非股动脉候选者替代手术的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access route for transcatheter aortic valve replacement (TAVR). However, scarce data exist on long-term outcomes following TC-TAVR. This study aimed to evaluate clinical outcomes at 5 years after TC-TAVR. METHODS: A total of 110 consecutive patients who underwent TC-TAVR were included. Baseline, procedural, and follow-up data were collected prospectively in a dedicated database. The primary endpoint was the incidence of a composite outcome of all-cause mortality, stroke, and repeat hospitalization at 5-year follow-up. Echocardiography results, New York Heart Association (NYHA) class, and quality of life (QoL) as assessed with the EuroQol visual analog scale (EQ-VAS) were examined over the 5-year follow-up. RESULTS: The median patient age was 77 years (interquartile range [IQR], 72-82.2 years), 42.3% were women, and the median Society of Thoracic Surgeons (STS) risk score was 5.02% (IQR, 3.4%-7.5%). The incidence of the composite primary endpoint was 54.5%. Death from any cause occurred in 45.6% of patients (11.9 per 100 patient-years); stroke in 8.2% (1.9 per 100 patient-years); disabling stroke in 2.7% (0.7 per 100 patient-years); and rehospitalization in 27.2%. The improvements in valve hemodynamics, NYHA class, and EQ-VAS following the procedure persisted at 5-year follow-up (P < .001). The incidence of bioprosthetic valve failure was 0.9%. CONCLUSIONS: About half of the moderate-to high-risk patients undergoing TC-TAVR survived with no major cardiovascular events at the 5-year follow-up. The yearly incidence of stroke events was low, and early improvements in valve hemodynamics, functional status, and QoL persisted at 5 years. These results suggest the long-term safety and efficacy of TC-TAVR and would support this approach as an alternative to surgery in non-transfemoral candidates.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Del Portillo JH, Kalavrouziotis D, Dumont E, et al. Five-year outcomes of transcarotid transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2024. PMID: 38936601. doi:10.1016/j.jtcvs.2024.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。